• A federal appeals court has blocked the mailing of mifepristone, the abortion pill.
• The ruling requires that the pill be distributed only in-person at clinics.
• This decision is expected to impact access to abortion nationwide, especially in rural areas.

A federal appeals court has effectively restricted access to one of the most common abortion methods in the U.S. with a ruling that blocks the mailing of mifepristone. A panel from the 5th U.S. Circuit Court of Appeals has mandated that the abortion pill must be distributed only in-person at clinics, reversing regulations that allowed for mail delivery. The ruling stems from a lawsuit initiated by Louisiana, which maintains stringent anti-abortion laws, asserting that mailing of prescriptions undermines state regulations, as stated in the panel’s decision: "Every abortion facilitated by FDA's action cancels Louisiana's ban on medical abortions..." according to NPR and LA Times.

The 5th Circuit’s ruling halts a 2023 FDA regulation that permitted the abortion pill to be prescribed and sent without in-person consultations, a significant shift since such permissions had been granted during the COVID-19 pandemic. Julia Kaye, an attorney with the ACLU, expressed that "losing a telemedicine option will mean losing access to this vital medication altogether," highlighting the adverse effects on marginalized communities, according to BBC and CBS News.

This decision is viewed as part of a broader legal battle in the wake of the Supreme Court's 2022 ruling that overturned Roe v. Wade, thus enabling states to effectuate stricter abortion bans. Following this landmark decision, remote prescriptions had become a key method of access, especially for those in states with severe restrictions. The potential appeal to the Supreme Court is anticipated, as previous rulings have upheld access to mifepristone despite political pressures, as noted by Le Monde and others.